Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPIMAPED imatinib discontinuation study in pediatric CML
NL-OMON23324Not yet recruiting
- Sponsor
- SKion
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by SKion. Primary endpoints: Molecular relapse-free survival at 6 and 24 months and Duration of complete molecular remission after stopping imatinib. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON23324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23324.